The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease: Comparative analysis according to fistula subtypes

Eun Jung Park, Ki Hwan Song, Seung Hyuk Baik, Jae Jun Park, Jeonghyun Kang, Kang Young Lee, Ja Il Goo, Namkyu Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Objective: Infliximab is regarded as an effective therapeutic to treat Crohn's disease. This study aimed to assess the efficacy of infliximab combined with surgery and to analyze clinical manifestations according to fistula subtypes in patients with fistulizing perianal Crohn's disease. Methods: From April 2013 to December 2015, 47 patients with perianal Crohn's disease in two hospitals of South Korea (Goo Hospital, Gangnam Severance Hospital) were evaluated retrospectively. Patients were categorized into two groups as simple fistula (n = 20) and complex fistula group (n = 27). All patients received 5 mg/kg of infliximab intravenously at 0, 2, and 6 weeks after surgical treatments. Then every eight weeks, the responders continued to receive 5 mg/kg infliximab for maintenance therapy. Results: Complete response of induction therapy was 72.3%, and partial response was 27.7%. After maintenance therapy, complete response was 97.9% and partial response was 2.1%. There was no patient without a response to infliximab in this study. The median time to the first fistula closure was 6.00 ± 8.00 weeks. Infliximab was used on average 2.13 ± 0.71 times until the first fistula closure. The rate of recurrence was 8.5% and adverse events were 4.2%. In comparison with clinical manifestations between simple and complex fistula groups, there was no significant difference except for the coexistence of perianal abscess. Conclusions: Combined surgical and infliximab therapy was efficacious to treat fistulizing perianal Crohn's disease with rapid treatment response and favorable clinical outcomes. It is expected that this top-down strategy with combining surgeries can overcome previous limitations in treating perianal Crohn's disease.

Original languageEnglish
Pages (from-to)438-447
Number of pages10
JournalAsian Journal of Surgery
Volume41
Issue number5
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Crohn Disease
Fistula
Therapeutics
Republic of Korea
Infliximab
Abscess
Recurrence

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Park, Eun Jung ; Song, Ki Hwan ; Baik, Seung Hyuk ; Park, Jae Jun ; Kang, Jeonghyun ; Lee, Kang Young ; Goo, Ja Il ; Kim, Namkyu. / The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease : Comparative analysis according to fistula subtypes. In: Asian Journal of Surgery. 2018 ; Vol. 41, No. 5. pp. 438-447.
@article{c1eac8ce19334dd994ee7aa45a92ce91,
title = "The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease: Comparative analysis according to fistula subtypes",
abstract = "Background/Objective: Infliximab is regarded as an effective therapeutic to treat Crohn's disease. This study aimed to assess the efficacy of infliximab combined with surgery and to analyze clinical manifestations according to fistula subtypes in patients with fistulizing perianal Crohn's disease. Methods: From April 2013 to December 2015, 47 patients with perianal Crohn's disease in two hospitals of South Korea (Goo Hospital, Gangnam Severance Hospital) were evaluated retrospectively. Patients were categorized into two groups as simple fistula (n = 20) and complex fistula group (n = 27). All patients received 5 mg/kg of infliximab intravenously at 0, 2, and 6 weeks after surgical treatments. Then every eight weeks, the responders continued to receive 5 mg/kg infliximab for maintenance therapy. Results: Complete response of induction therapy was 72.3{\%}, and partial response was 27.7{\%}. After maintenance therapy, complete response was 97.9{\%} and partial response was 2.1{\%}. There was no patient without a response to infliximab in this study. The median time to the first fistula closure was 6.00 ± 8.00 weeks. Infliximab was used on average 2.13 ± 0.71 times until the first fistula closure. The rate of recurrence was 8.5{\%} and adverse events were 4.2{\%}. In comparison with clinical manifestations between simple and complex fistula groups, there was no significant difference except for the coexistence of perianal abscess. Conclusions: Combined surgical and infliximab therapy was efficacious to treat fistulizing perianal Crohn's disease with rapid treatment response and favorable clinical outcomes. It is expected that this top-down strategy with combining surgeries can overcome previous limitations in treating perianal Crohn's disease.",
author = "Park, {Eun Jung} and Song, {Ki Hwan} and Baik, {Seung Hyuk} and Park, {Jae Jun} and Jeonghyun Kang and Lee, {Kang Young} and Goo, {Ja Il} and Namkyu Kim",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.asjsur.2017.06.005",
language = "English",
volume = "41",
pages = "438--447",
journal = "Asian Journal of Surgery",
issn = "1015-9584",
publisher = "Elsevier Taiwan LLC",
number = "5",

}

The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease : Comparative analysis according to fistula subtypes. / Park, Eun Jung; Song, Ki Hwan; Baik, Seung Hyuk; Park, Jae Jun; Kang, Jeonghyun; Lee, Kang Young; Goo, Ja Il; Kim, Namkyu.

In: Asian Journal of Surgery, Vol. 41, No. 5, 01.09.2018, p. 438-447.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease

T2 - Comparative analysis according to fistula subtypes

AU - Park, Eun Jung

AU - Song, Ki Hwan

AU - Baik, Seung Hyuk

AU - Park, Jae Jun

AU - Kang, Jeonghyun

AU - Lee, Kang Young

AU - Goo, Ja Il

AU - Kim, Namkyu

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background/Objective: Infliximab is regarded as an effective therapeutic to treat Crohn's disease. This study aimed to assess the efficacy of infliximab combined with surgery and to analyze clinical manifestations according to fistula subtypes in patients with fistulizing perianal Crohn's disease. Methods: From April 2013 to December 2015, 47 patients with perianal Crohn's disease in two hospitals of South Korea (Goo Hospital, Gangnam Severance Hospital) were evaluated retrospectively. Patients were categorized into two groups as simple fistula (n = 20) and complex fistula group (n = 27). All patients received 5 mg/kg of infliximab intravenously at 0, 2, and 6 weeks after surgical treatments. Then every eight weeks, the responders continued to receive 5 mg/kg infliximab for maintenance therapy. Results: Complete response of induction therapy was 72.3%, and partial response was 27.7%. After maintenance therapy, complete response was 97.9% and partial response was 2.1%. There was no patient without a response to infliximab in this study. The median time to the first fistula closure was 6.00 ± 8.00 weeks. Infliximab was used on average 2.13 ± 0.71 times until the first fistula closure. The rate of recurrence was 8.5% and adverse events were 4.2%. In comparison with clinical manifestations between simple and complex fistula groups, there was no significant difference except for the coexistence of perianal abscess. Conclusions: Combined surgical and infliximab therapy was efficacious to treat fistulizing perianal Crohn's disease with rapid treatment response and favorable clinical outcomes. It is expected that this top-down strategy with combining surgeries can overcome previous limitations in treating perianal Crohn's disease.

AB - Background/Objective: Infliximab is regarded as an effective therapeutic to treat Crohn's disease. This study aimed to assess the efficacy of infliximab combined with surgery and to analyze clinical manifestations according to fistula subtypes in patients with fistulizing perianal Crohn's disease. Methods: From April 2013 to December 2015, 47 patients with perianal Crohn's disease in two hospitals of South Korea (Goo Hospital, Gangnam Severance Hospital) were evaluated retrospectively. Patients were categorized into two groups as simple fistula (n = 20) and complex fistula group (n = 27). All patients received 5 mg/kg of infliximab intravenously at 0, 2, and 6 weeks after surgical treatments. Then every eight weeks, the responders continued to receive 5 mg/kg infliximab for maintenance therapy. Results: Complete response of induction therapy was 72.3%, and partial response was 27.7%. After maintenance therapy, complete response was 97.9% and partial response was 2.1%. There was no patient without a response to infliximab in this study. The median time to the first fistula closure was 6.00 ± 8.00 weeks. Infliximab was used on average 2.13 ± 0.71 times until the first fistula closure. The rate of recurrence was 8.5% and adverse events were 4.2%. In comparison with clinical manifestations between simple and complex fistula groups, there was no significant difference except for the coexistence of perianal abscess. Conclusions: Combined surgical and infliximab therapy was efficacious to treat fistulizing perianal Crohn's disease with rapid treatment response and favorable clinical outcomes. It is expected that this top-down strategy with combining surgeries can overcome previous limitations in treating perianal Crohn's disease.

UR - http://www.scopus.com/inward/record.url?scp=85028414178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028414178&partnerID=8YFLogxK

U2 - 10.1016/j.asjsur.2017.06.005

DO - 10.1016/j.asjsur.2017.06.005

M3 - Article

C2 - 28851611

AN - SCOPUS:85028414178

VL - 41

SP - 438

EP - 447

JO - Asian Journal of Surgery

JF - Asian Journal of Surgery

SN - 1015-9584

IS - 5

ER -